CT radiomics and PET radiomics: ready for clinical implementation?
Today, rapid technical and clinical developments result in an increasing number of treatment options for oncological diseases. Thus, decision support systems are needed to offer the right treatment to the right patient. Imaging biomarkers hold great promise in patient-individual treatment guidance. Routinely performed for diagnosis and staging, imaging datasets are excepted to hold more information than used in the clinical practice. Radiomics describes the extraction of a large number of meaningful quantitative features from medical images, such as computed tomography (CT) and positron emission tomography (PET). Due to the non-invasive nature and ability to capture 3D image-based heterogeneity, radiomic features are potential surrogate markers of the cancer phenotype. Several radiomic studies are published per day, owing to encouraging results of many radiomics-based patient outcome models. Despite this comparably large number of studies, radiomics is mainly studied in proof of principle concept. Hence, a translation of radiomics from a hot topic research field into an essential clinical decision making tool is lacking, but of high clinical interest. Herein, we present a literature review addressing the clinical evidence of CT and PET radiomics. We summarize image-modality related influences on the robustness of radiomic features and provide an overview of clinical evidence reported in the literature. At the end, we provide a summary of future research directions, which need to be addressed to successfully introduce radiomics into clinical medicine.